Indantadol

Indantadol

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name N-(2,3-dihydro-1H-inden-2-yl)glycinamide
CAS Number	202844-10-8
ChemSpider	16017060
UNII	Z3867B9SQP
CompTox Dashboard (EPA)	DTXSID00942416
Chemical and physical data
Formula	C11H14N2O
Molar mass	190.246 g·mol−1
3D model (JSmol)	Interactive image
SMILES NCC(=O)NC1Cc2ccccc2C1

Indantadol (CHF-3381, V-3381) is a drug which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials.

See also

• 2-Aminoindane
• Glycine